Syntara Limited
Business Services · Australia · 51-200 Employees
View Company Info for Free
Overview
Headquarters
PO Box, Frenchs Forest, New South Wales,...Phone Number
+61 294547200Website
www.syntaratx.com.auRevenue
$6.2 MillionStock Symbol
SNTIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Syntara Limited
Syntara is a clinical-stage drug development company focused on creating innovative treatments for blood-related cancers and conditions associated with inflammation and fibrosis. The company specializes in addressing extracellular matrix dysfunction through its expertise in amine oxidase chemistry. Its lead candidate, amsulostat, is currently undergoing Phase 2 trials for myelofibrosis, with additional studies in myelodysplastic syndrome and other chronic diseases. Syntara aims to provide life-changing therapies for patients with high unmet medical needs.Explore more
Syntara Limited Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Syntara Limited your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Syntara Limited is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Syntara Limited had a recent Job posting/layoffs
Syntara Limited, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Syntara Limited has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Syntara Limited launches new products
Funding: Get notified immidiatlly once Syntara Limited has new funding data
Earning: See what the market has to say on Syntara Limited recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Syntara Limited
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Syntara Limited
Compare insights from companies similar to Syntara Limited, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Syntara Limited is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Syntara Limited is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Syntara Limited.
Most Recent Scoops
Project
Syntara Limited has identified an estimated AUD 1 billion add-on market opportunity for amsulostat in myelofibrosis, based on the FDA-endorsed development pathway positioning the drug as an add-on therapy to JAK inhibitors in suboptimally controlled patients, within a JAK inhibitor market of approximately USD 1.8 to 2 billion in annual sales, with ruxolitinib coming off patent in 2028.
Pharmaceuticals
Project
expects to receive full phase II results for SNT-4728 toward the end of Q3 of the current calendar year, following which the company plans to engage with global philanthropic organizations and CNS-specialist companies regarding the drug's development pathway.
Product Development, Pharmaceuticals
Project
Syntara Limited has reported that open-label phase IIa data for amsulostat in myelofibrosis demonstrates symptom score improvement competitive with or superior to other drugs in development or on the market, with symptom improvement observed from three months, earlier than the expected six-month timeframe, alongside competitive spleen volume reduction and a favorable tolerability profile with no hematological toxicity.
Medical Research, Pharmaceuticals
Project
Syntara Limited has received positive FDA feedback on the clinical development pathway for amsulostat in myelofibrosis, resulting in broad agreement on a protocol for a phase IIb study. This outcome de-risks the asset by establishing an FDA-endorsed development pathway and resolving outstanding regulatory questions.
Clinical Operations
Project
Proof of Concept (POC), Medical Research
Syntara Limited News & Media
Syntara Limited (PMXSF) Shareholder/Analyst Call Prepared Remarks Transcript
Syntara Limited (PMXSF) Shareholder/Analyst Call June 22, 2026 8:01 PM EDTCompany ParticipantsTim Luscombe - CFO & Company SecretaryKathleen M.Syntara secures capital raise to advance amsulostat trials and strengthen pipeline - Biotech
Syntara CEO Gary Phillips said, “We’re very grateful for the strong support from our shareholders and new investors in this capital raising, stemming from the positive FDA review of our clinical development plan and Phase 2b protocol for amsulostat."Syntara Limited (PMXSF) Discusses 2026 Clinical Pipeline Outlook and Anticipated Trial Updates Transcript
Syntara Limited (PMXSF) Discusses 2026 Clinical Pipeline Outlook and Anticipated Trial Updates February 2, 2026 7:01 PM ESTCompany ParticipantsGary Phillips...We're Keeping An Eye On Syntara's (ASX:SNT) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Read more news
Top Business Services Companies
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Syntara Limited
Sign Up For FreeTo access detailed company insights
Syntara is a clinical-stage drug development company focused on creating innovative treatments for blood-related cancers and conditions associated with inflammation and fibrosis. The company specializes in addressing extracellular matrix dysfunction through its expertise in amine oxidase chemistry. Its lead candidate, amsulostat, is currently under... Read More
